Chest, Vol 95, 563-567, Copyright © 1989 by American College of Chest Physicians

ARTICLES

A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD

CL Emerman, AF Connors, TW Lukens, ME May and D Effron
Department of Emergency Medicine, Cleveland Metropolitan General Hospital, Ohio.

We conducted a randomized, controlled double-blind study to determine whether intravenous administration of methylprednisolone early in the therapy for acute exacerbations of COPD would improve pulmonary function in the Emergency Department and reduce the need for hospitalization. Ninety-six patients completed the study. All were at least 50 years of age and had no history of asthma. Patients received aminophylline and hourly administration of aerosolized isoetharine. Methylprednisolone (100 mg) or physiologic saline solution was given within one-half hour of arrival in the Emergency Department. Spirometry was performed initially and after the third and fifth aerosol treatments. We found no greater improvement in FEV1 in the group receiving the steroid (37 percent) than in the control group (43 percent; NS). There was also no difference in the rate of hospitalization (33 percent in the steroid-treated group vs 30 percent in the control group; NS). We conclude that early administration of methylprednisolone does not affect the emergency phase of treatment for acute exacerbations of COPD.

This article has been cited by other articles:

				B. S. Quon, W. Q. Gan, and D. D. Sin Contemporary Management of Acute Exacerbations of COPD: A Systematic Review and Metaanalysis Chest, March 1, 2008; 133(3): 756 - 766. [Abstract] [Full Text] [PDF]

				Y. P. de Jong, S. M. Uil, H. P. Grotjohan, D. S. Postma, H. A.M. Kerstjens, and J. W.K. van den Berg Oral or IV Prednisolone in the Treatment of COPD Exacerbations: A Randomized, Controlled, Double-blind Study Chest, December 1, 2007; 132(6): 1741 - 1747. [Abstract] [Full Text] [PDF]

				J. A. Wedzicha Role of Viruses in Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2004; 1(2): 115 - 120. [Abstract] [Full Text] [PDF]

				S. Nava From the Author Eur. Respir. J., February 1, 2003; 21(2): 378 - 378. [Full Text] [PDF]

				J. M. Singh, V. A. Palda, M. B. Stanbrook, and K. R. Chapman Corticosteroid Therapy for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review Arch Intern Med, December 9, 2002; 162(22): 2527 - 2536. [Abstract] [Full Text] [PDF]

				J. A. Wedzicha Exacerbations* : Etiology and Pathophysiologic Mechanisms Chest, May 1, 2002; 121(5_suppl): 136S - 141S. [Abstract] [Full Text] [PDF]

				D. C. McCrory, C. Brown, S. E. Gelfand, and P. B. Bach Management of Acute Exacerbations of COPD : A Summary and Appraisal of Published Evidence Chest, April 1, 2001; 119(4): 1190 - 1209. [Abstract] [Full Text] [PDF]

				A. Sayiner, Z. A. Aytemur, M. Cirit, and I. Unsal Systemic Glucocorticoids in Severe Exacerbations of COPD Chest, March 1, 2001; 119(3): 726 - 730. [Abstract] [Full Text] [PDF]

				D. E. NIEWOEHNER, D. COLLINS, and M. L.E. f. t. D. o.  Veterans Affairs Cooperative Study Relation of FEV1 to Clinical Outcomes during Exacerbations of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1201 - 1205. [Abstract] [Full Text]

				M. A. JANTZ and S. A. SAHN Corticosteroids in Acute Respiratory Failure Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1079 - 1100. [Full Text]

				D. E. Niewoehner, M. L. Erbland, R. H. Deupree, D. Collins, N. J. Gross, R. W. Light, P. Anderson, N. A. Morgan, and The Department of Veterans Affairs Cooperative Stu Effect of Systemic Glucocorticoids on Exacerbations of Chronic Obstructive Pulmonary Disease N. Engl. J. Med., June 24, 1999; 340(25): 1941 - 1947. [Abstract] [Full Text] [PDF]

				S. E. Weinberger Recent Advances in Pulmonary Medicine- First of Two Parts N. Engl. J. Med., May 13, 1993; 328(19): 1389 - 1397. [Full Text]